Fluctuations of CSF amyloid-β levels -: Implications for a diagnostic and therapeutic biomarker

被引：200

作者：

Bateman, Randall J.

Wen, Guolin

Morris, John C.

Holtzman, David M.

机构：

[1] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA

[2] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA

[3] Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA

[4] Washington Univ, Sch Med, Alzheimers Dis Res Ctr, St Louis, MO 63110 USA

[5] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA

来源：

NEUROLOGY | 2007年 / 68卷 / 09期

关键词：

D O I：

10.1212/01.wnl.0000256043.50901.e3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To investigate the stability and time course of human CSF amyloid-beta (A beta) levels over hours. Methods: Fifteen nondemented participants had CSF sampled hourly for up to 36 hours via indwelling lumbar catheter. CSF A beta(1-x), A beta(1-40), and A beta(1-42) were measured by ELISA in each hourly CSF sample. Results: Significant variation in A beta levels of 1.5- to fourfold was detected over 36 hours of serially sampling in individual subjects. A beta(40), A beta(42), and A beta(1-X) are highly correlated over time indicating that similar processes likely regulate the level of these species. On average, the fluctuations of A beta levels appear to be time of day or activity dependent. Conclusion: Diagnostic and therapeutic trials that measure A beta should control for the time of CSF sampling to minimize variability.

引用

页码：666 / 669

页数：4

共 15 条

[1] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease [J].